Rani Therapeutics (RANI) to Release Earnings on Thursday

Rani Therapeutics (NASDAQ:RANI) is projected to issue its Q2 2026 results before the market opens on Thursday, August 6th. Analysts expect the company to announce earnings of ($0.05) per share and revenue of $0.9250 million for the quarter. Parties may review the information on the company’s upcoming Q2 2026 earning report page for the latest details on the call scheduled for Friday, August 14, 2026 at 4:00 PM ET.

Rani Therapeutics (NASDAQ:RANI) last posted its earnings results on Friday, May 15th. The company reported ($0.04) EPS for the quarter, beating analysts’ consensus estimates of ($0.06) by $0.02. The firm had revenue of $1.71 million for the quarter, compared to analysts’ expectations of $1.12 million. On average, analysts expect Rani Therapeutics to post $-0 EPS for the current fiscal year and $-0 EPS for the next fiscal year.

Rani Therapeutics Stock Up 3.0%

Shares of RANI opened at $0.84 on Thursday. The company has a 50 day moving average of $0.80 and a two-hundred day moving average of $1.02. Rani Therapeutics has a twelve month low of $0.44 and a twelve month high of $3.87. The company has a market cap of $104.54 million, a price-to-earnings ratio of -2.06 and a beta of 0.78.

Analysts Set New Price Targets

Several brokerages have recently commented on RANI. Canaccord Genuity Group reiterated a “buy” rating and set a $5.00 price objective on shares of Rani Therapeutics in a report on Wednesday, May 20th. Wall Street Zen upgraded Rani Therapeutics from a “sell” rating to a “hold” rating in a research note on Sunday, May 17th. Lake Street Capital began coverage on Rani Therapeutics in a research report on Tuesday, April 14th. They set a “buy” rating and a $9.00 target price on the stock. Finally, Weiss Ratings cut Rani Therapeutics from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Friday, July 17th. Four investment analysts have rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average target price of $8.75.

Insider Activity

In related news, CEO Talat Imran acquired 35,000 shares of the stock in a transaction dated Friday, July 17th. The stock was acquired at an average cost of $0.72 per share, for a total transaction of $25,200.00. Following the completion of the purchase, the chief executive officer owned 469,736 shares of the company’s stock, valued at approximately $338,209.92. This represents a 8.05% increase in their position. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Corporate insiders own 26.73% of the company’s stock.

Hedge Funds Weigh In On Rani Therapeutics

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Virtu Financial LLC acquired a new stake in Rani Therapeutics during the 4th quarter worth about $69,000. OMERS ADMINISTRATION Corp acquired a new position in shares of Rani Therapeutics in the fourth quarter valued at about $93,000. Farallon Capital Management LLC purchased a new position in shares of Rani Therapeutics in the fourth quarter worth about $105,000. Bridgeway Capital Management LLC purchased a new position in shares of Rani Therapeutics in the fourth quarter worth about $155,000. Finally, Millennium Management LLC acquired a new stake in shares of Rani Therapeutics during the fourth quarter worth about $220,000. Hedge funds and other institutional investors own 30.19% of the company’s stock.

About Rani Therapeutics

Rani Therapeutics is a clinical-stage biopharmaceutical company developing oral delivery technologies for large-molecule drugs. The company’s proprietary RaniPill platform is designed to enable the gastrointestinal delivery of biologic therapies traditionally administered via injection. Through a swallowable capsule that autonomously deploys a microscopic injector in the small intestine, Rani aims to improve patient convenience and adherence for peptide and protein therapies, including insulin and other hormones.

Since its founding in 2012, Rani Therapeutics has advanced its lead programs through early-phase clinical trials, demonstrating proof-of-concept for oral insulin delivery.